Natera Improves Price Strength with IBD Rating Upgrade to 78
July 13, 2023
☀️Trending News
Natera ($NASDAQ:NTRA) is an innovative biotechnology company with a focus on developing products for prenatal genetics and diagnostics. Primarily known for its non-invasive genetic testing, Natera’s offerings are used in reproductive health, oncology, and organ transplantation. On Tuesday, Natera’s Relative Strength Rating saw an improvement, from 66 to 78, indicating an increase in price strength. One factor to watch closely when searching for stocks to buy and watch is relative price strength. With a 78 rating, Natera is among the stocks rated as strong performers.
This increase in price strength can be seen as a sign of potential future growth for the company. Overall, Natera’s improved Relative Strength Rating is an encouraging sign for investors looking to buy and watch the stock. With a 78 rating, Natera appears to be among the stronger performers in its industry. Investors should continue to monitor Natera closely to evaluate any changes in the company’s performance and price strength.
Price History
On Tuesday, NATERA stock opened at $48.1 and closed at $49.0, representing a 1.4% increase from its last closing price of 48.3. The company has shown strength in multiple aspects, including strong cash flow, efficient operations, and attractive returns on equity. In addition, Natera’s market share has been expanding in the past year and its products have become increasingly popular among customers. This upgrade in IBD rating is a clear sign that NATERA is continuing to make progress towards becoming a market leader. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Natera. More…
| Total Revenues | Net Income | Net Margin |
| 867.85 | -546.14 | -62.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Natera. More…
| Operations | Investing | Financing |
| -375.11 | 138.96 | 480.79 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Natera. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.32k | 668.31 | 5.74 |
Key Ratios Snapshot
Some of the financial key ratios for Natera are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 38.1% | – | -61.6% |
| FCF Margin | ROE | ROA |
| -48.2% | -49.3% | -25.3% |
Analysis
At GoodWhale, we have conducted an analysis of NATERA‘s fundamentals and have classified the company as a ‘cheetah’ based on our Star Chart. This type of company is one that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Given this classification, investors who may be interested in such a company are those who are more focused on capital appreciation rather than income generation. This type of investor may be willing to accept higher levels of risk in return for potentially higher returns. However, NATERA has a low health score of 3/10 considering its cashflows and debt, which suggests that it is less likely to sustain future operations in times of crisis. Additionally, it is also weak in dividend and profitability, but is strong in asset and growth. Therefore, potential investors should consider these features carefully before investing. More…
Peers
The company’s products are used for pregnancy and fertility testing, as well as for cancer and inherited disease risk assessment. Natera‘s competitors include Genetic Technologies Ltd, Dr Lalchandani Labs Ltd, and NeoGenomics Inc.
– Genetic Technologies Ltd ($ASX:GTG)
Genetic Technologies Ltd is a biotechnology company that develops and commercializes molecular diagnostic tests. The company has a market cap of 27.7M as of 2022 and a Return on Equity of -24.9%. The company’s products are used for the detection of genetic disorders and cancer.
– Dr Lalchandani Labs Ltd ($BSE:541299)
Lalchandani Labs Ltd is a pharmaceutical company with a market cap of 141.91M as of 2022. The company has a Return on Equity of 12.87%. The company manufactures and sells pharmaceutical products and services. It offers products and services in the areas of diagnostics, therapeutics, and general health care. The company also provides services in the areas of research and development, manufacturing, marketing, and sales.
– NeoGenomics Inc ($NASDAQ:NEO)
NeoGenomics, Inc. is a holding company, which engages in the business of providing cancer-focused genetic testing services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment includes tumor tissue tests, fluid tests, and other ancillary tests. The Pharma Services segment provides genomic services to pharmaceutical clients to support their drug development programs. The company was founded by Douglas M. Ross in 2001 and is headquartered in Fort Myers, FL.
Summary
Natera is a biomedical technology company that recently received an upgrade to its Relative Strength Rating from 66 to 78. This indicates improved price strength and suggests that this stock may be a good option for investors to consider. The improvement was based on a number of criteria, including short-term technical indicators, analyst sentiment, and fundamentals like earnings and revenue growth. With this upgrade, Natera may become an attractive investment option for those looking for a portfolio boost.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
